Jugl, SM : rechercher sur Z-Library

Le plus grand référentiel d'articles scientifiques au monde. 70,000,000+ d'articles gratuitement.

Don't use scam websites

Livres
Articles (37)
Les plus populaires
Liste
- Liste
- Tableau

1

UNDERSTANDING THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI), PSORIASIS AREA SEVERITY INDEX (PASI), AND QUALITY OF LIFE (QOL) AND ITS INFLUENCE ON COST-EFFECTIVENESS IN PSORIATIC ARTHRITIS (PSA)

Gunda, P, Syeda, SS, Jugl, SM

Journal:

Value in Health

Année:

2015

Langue:

english

Fichier:

PDF, 52 KB

english, 2015

2

Review of Patient Reported Outcome Measures used in Clinical and Cost-Effectiveness Studies to Measure Utilities in the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

Syeda, SS, Jugl, SM, Gunda, P

Journal:

Value in Health

Année:

2015

Langue:

english

Fichier:

PDF, 51 KB

english, 2015

3

Matching Adjusted Indirect Comparisons To Assess Comparative Effectiveness Of Therapies: Usage In Scientific Literature And Health Technology Appraisals

Thom, H, Jugl, SM, Palaka, E, Jawla, S

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 80 KB

english, 2016

4

Psoriatic Arthritis Response Criteria Scores: Results From A Placebo-Response Adjusted Network Meta-Analysis With Secukinumab

Thom, H, Jugl, SM, McInnes, I, Nash, P, Ritchlin, C, Kanters, S, Palaka, E, Gandhi, K, Mpofu, S

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 64 KB

english, 2016

5

Epidemiology and Costs of Psoriatic Arthritis in Germany – A Retrospective Claims Data Analysis

Jacob, C, Meier, F, Neidhardt, K, Jugl, SM, Walker, J, Braun, S, Augustin, M

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 70 KB

english, 2016

6

Budget Impact of Secukinumab For Ankylosing Spondylitis In The UK

Halliday, A, Hacking, V, Jugl, SM, Gunda, P, Nikoglou, E, Miles, L, Graham, CN

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 66 KB

english, 2016

7

Epidemiology and Costs of Psoriasis in Germany – A Retrospective Claims Data Analysis

Jacob, C, Meier, F, Neidhardt, K, Jugl, SM, Walker, J, Braun, S, Augustin, M

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 70 KB

english, 2016

8

A Cost Per Responder Analysis of Secukinumab Vs Adalimumab Based on A Matching-Adjusted Indirect Comparison For The Treatment of Ankylosing Spondylitis From A German Payer Perspective

Gunda, P, Kandhare, A, Nikoglou, E, Jugl, SM, Kneidl, J, Neidhardt, K

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 63 KB

english, 2016

9

Assessing The Cost-Effectiveness of Secukinumab Compared To Tnf Inhibitors As Second Line Biologic Treatment In Psoriatic Arthritis

Lang, A, Costa-Scharplatz, M, Fasth, A, Gunda, P, Jugl, SM, Jacobsson, L

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 68 KB

english, 2016

10

Ankylosing Spondylitis is Associated with Significant Increases in Healthcare Resource Utilization And Costs in A German Real World Setting

Krueger, K, von Hinueber, U, Meier, F, Meise, D, Braun, S, Tian, H, Neidhardt, K, Jugl, SM, Borchert, K

Journal:

Value in Health

Année:

2016

Langue:

english

Fichier:

PDF, 68 KB

english, 2016

11

Ankylosing Spondylitis Limits Patients’ Ability to Contribute to Society As Part of the Workforce: Results from A Multi-National Survey Including Latin America

Deodhar, A, Conaghan, PG, Alten, R, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Strand, V

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

12

Assessing The Disease Course And Treatment of Psoriatic Arthritis (PSA) In Canada

MacPherson, A, Chiva-Razavi, S, Barbeau, M, Piercy, J, Blackburn, S, Sullivan, E, Tian, H, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

13

Secukinumab vs Adalimumab for The Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis at 52 Weeks from A Brazilian Perspective

Lopes, N, Suzuki, C, Barbeau, M, MacPherson, A, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 59 KB

english, 2017

14

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondilytis: A Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective

Kooli, A, Gunda, P, Toumi, J, Nikoglou, E, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 60 KB

english, 2017

15

A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatmetn of Psoriatic Arthritis at 48 Weeks from the Irish Payer Perspective

Gunda, P, Nikoglou, E, Jugl, SM, Murphy, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 76 KB

english, 2017

16

Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis as Assessed by Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data

Maksymowych, WP, Walsh, J, Thom, H, Kalyvas, C, Rosal, GF, Porter, B, Gandhi, K, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

17

Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective

Barbeau, M, Bianculli, PM, Nikoglou, E, Gunda, P, Jugl, SM, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 58 KB

english, 2017

18

Cost-Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

Emery, P, van Keep, M, Beard, SM, Graham, CN, Miles, L, Jugl, SM, Gunda, P, Halliday, A, Marzo-Ortega, H

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 65 KB

english, 2017

19

Secukinumab Shows Higher Symptomatic improvement Versus Infliximab in Psoriatic Arthritis: Comparative Effectiveness Up To 1 Year Assessed by Matching-Adjusted Indirect Comparisons

Strand, V, McInnes, I, Thom, H, Hunger, M, Lopes, N, Gandhi, K, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 82 KB

english, 2017

20

Comparison of Secukinumab Vs Infliximab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective

Kooli, A, Gunda, P, Toumi, J, Nikoglou, E, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 62 KB

english, 2017

21

Secukinumab vs. Adalimumab for the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis at 48 Weeks from a Brazilian Perspective

Lopes, N, Suzuki, C, Barbeau, M, MacPherson, A, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 59 KB

english, 2017

22

Psoriatic Arthritis Limits Patients’ Ability to Contribute to Society As Part of the Workforce: Results from A Multi-National Survey Including Latin America

Scheinberg, M, Conaghan, PG, Alten, R, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Strand, V

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

23

Delayed Biologic Switching Among Ankylosing Spondylitis (As) Patients May Result in Poor Health- Related Quality of Life: Results From A Multi-National Survey Including Latin America

Pereira, I, Alten, R, Conaghan, PG, Strand, V, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Deodhar, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

24

Appropriate Ankylosing Spondylitis (AS) Treatment is Delayed For Years: Results From a Multi-National Survey Including Latin America

Pinheiro, M, Strand, V, Alten, R, Conaghan, PG, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Deodhar, A

Journal:

Value in Health

Année:

2017

Fichier:

PDF, 62 KB

2017

25

Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective

Rojas, R, Barbeau, M, Jugl, SM, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 77 KB

english, 2017

26

Secukinumab shows Higher Symptomatic improvement Versus Etanercept in Psoriatic Arthritis: Comparative Effectiveness Up To 24 Weeks Assessed by Matching-Adjusted Indirect Comparison

Mease, P, Choy, E, Thom, H, Kalyvas, C, Lopes, N, Pricop, L, Gandhi, K, Jugl, SM, Nash, P

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 62 KB

english, 2017

27

Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis: Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons

Thom, H, Hunger, M, Rosal, GF, Gandhi, K, Jugl, SM, Nash, P

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

28

Delayed Biologic Switching Among Psoriatic Arthritis (Psa) Patients May Result in Poor Health-Related Quality of Life: Results From A Multi-National Survey Including Latin America

Ranza, R, Alten, R, Strand, V, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Conaghan, PG

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

29

Assessing the Burden of Disease in Peripheral and Axial Spondyloarthritis in Mexico and Brazil

Romo, X, Piercy, J, Blackburn, S, Lopes, N, Jugl, SM, MacPherson, A, Barbeau, M

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 62 KB

english, 2017

30

Secukinumab Shows Higher Symptomatic Improvement and Lower Cost Per Response vs. Adalimumab After One Year Treatment of Active Ankylosing Spondylitis: A Cost Per Responder Analysis from A Chilean Perspective

Rojas, R, Barbeau, M, Jugl, SM, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 58 KB

english, 2017

31

A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Ankylosing Spondylitis at 52 Weeks from the Irish Payer Perspective

Gunda, P, Nikoglou, E, Jugl, SM, Murphy, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 58 KB

english, 2017

32

Appropriate Psoriatic Arthritis Treatment is Delayed for Years: Results From a Multi-National Survey Including Latin America

Azevedo, VF, Conaghan, PG, Strand, V, Sullivan, E, Blackburn, S, Tian, H, Gandhi, K, Jugl, SM, Alten, R

Journal:

Value in Health

Année:

2017

Fichier:

PDF, 62 KB

2017

33

Assessing The Burden of Disease In Peripheral And Axial Spondyloarthritis In Mexico

Barbeau, M, Sullivan, E, Blackburn, S, Piercy, J, Romo, X, Jugl, SM, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 62 KB

english, 2017

34

Comparison Ofsecukinumab Vs Adalimumab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective

Kooli, A, Gunda, P, Toumi, J, Nikoglou, E, Jugl, SM

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 61 KB

english, 2017

35

Assessing The Burden of Disease In Peripheral And Axial Spondyloarthritis In Brazil

Lopes, N, Sullivan, E, Blackburn, S, Piercy, J, Jugl, SM, Barbeau, M, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 62 KB

english, 2017

36

Secukinumab Vs. Adalimumab for the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis at 48 Weeks from an Argentinian Perspective

Barbeau, M, Bianculli, PM, Nikoglou, E, Gunda, P, Jugl, SM, MacPherson, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 82 KB

english, 2017

37

Cost-Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

Kirkham, B, Buchanan, V, Sullivan, W, Graham, CN, Miles, L, Jugl, SM, Gunda, P, Halliday, A

Journal:

Value in Health

Année:

2017

Langue:

english

Fichier:

PDF, 60 KB

english, 2017